Treatment of refractory diffuse large B-cell lymphoma involving the central nervous system with polatuzumab vedotin-based regimen: a case report and literature review
10.3760/cma.j.cn121090-20240119-00035
- VernacularTitle:以维泊妥珠单抗为基础方案治疗中枢神经系统累及的难治性弥漫大B细胞淋巴瘤1例报告并文献复习
- Author:
Jiefei BAI
1
;
Ru FENG
;
Ting WANG
;
Xu LI
;
Long QIAN
;
Jiangtao LI
;
Chunli ZHANG
;
Hui LIU
Author Information
1. 北京医院血液内科，国家老年医学中心，中国医学科学院老年医学研究院，北京 100730
- From:
Chinese Journal of Hematology
2024;45(9):864-866
- CountryChina
- Language:Chinese
-
Abstract:
Polatuzumab vedotin (Pola) is a novel antibody-drug conjugate targeting CD79b, which has been shown to be effective in treating newly diagnosed and relapsed/refractory diffuse large B cell lymphoma (DLBCL) during clinical trials. This study aims to conduct a retrospective analysis of the clinical characteristics, diagnosis, and treatment of a patient with refractory secondary central nervous system lymphoma at Beijing Hospital, alongside a review of relevant literature. This study included a 79-year-old female patient who was diagnosed with DLBCL affecting the ilium, sacrum, spinal cord, and nerve roots and had an IPI score of 5 and a high-risk score according to MSKCC. She showed a geriatric comprehensive assessment (IACA) score of 2, which was categorized under the unfit group. Her initial treatment comprised chemo-free therapy and radiotherapy, followed by progression. In the second-line treatment, a Pola-based regimen was applied, and the patient achieved a complete response, suggesting that this regimen may be a therapeutic option for patients with DLBCL involving the central nervous system.
